Steris (NYSE: STE) and Histogenics (NASDAQ:HSGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Steris pays an annual dividend of $1.24 per share and has a dividend yield of 1.2%. Histogenics does not pay a dividend. Steris pays out 29.9% of its earnings in the form of a dividend. Steris has raised its dividend for 8 consecutive years.
This table compares Steris and Histogenics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Steris and Histogenics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Steris||$2.62 billion||3.39||$290.91 million||$4.15||25.30|
Steris has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than Steris, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
90.7% of Steris shares are held by institutional investors. Comparatively, 46.3% of Histogenics shares are held by institutional investors. 2.4% of Steris shares are held by company insiders. Comparatively, 19.7% of Histogenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Steris has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Histogenics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Steris and Histogenics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Steris presently has a consensus price target of $80.25, suggesting a potential downside of 23.58%. Histogenics has a consensus price target of $4.00, suggesting a potential upside of 60.00%. Given Histogenics’ stronger consensus rating and higher probable upside, analysts clearly believe Histogenics is more favorable than Steris.
Steris beats Histogenics on 10 of the 15 factors compared between the two stocks.
Steris Company Profile
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories. It also provides OR integration, OR and sterile processing department, workflow, patient tracking, and instrument management solutions; and cleaning chemistries and sterility assurance products. In addition, this segment offers preventive maintenance and repair, sterilization and surgical management consulting, and remote equipment monitoring services, as well as other support services. The company's Healthcare Specialty Services segment provides solutions, and outsourced and managed services for acute care hospitals and other healthcare settings, including instrument and endoscope repair and maintenance solutions; and custom process improvement consulting services. Its Life Sciences segment offers formulated cleaning chemistries, vaporized hydrogen peroxide generators, high-purity water equipment, steam sterilizers, and washers/disinfectors. The company's Applied Sterilization Technologies segment provides contract sterilization services using gamma, electron beam, and X-ray technologies, as well as ethylene oxide gas; and laboratory testing and validation services. It operates a network of 50 facilities. The company was founded in 1985 and is headquartered in Leicester, the United Kingdom.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.